Zealand Pharma

Share Issue/Capital Change • Jun 2, 2015

Copenhagen, 2015-06-02 15:39 CEST (GLOBE NEWSWIRE) -- Copenhagen, 2 June 2015 -
Zealand Pharma A/S (Nasdaq OMX Copenhagen A/S: ZEAL) (“Zealand”) announces that
the company’s share capital has been increased by nominal DKK 51,487 divided
into 51,487 new shares with a nominal value of DKK 1 each. The increase is a
consequence of the exercise of employee warrants granted under two of the
company's warrant programs as described in the Articles of Association.

The subscription price is DKK 94.60 per share for 33,506 of the new shares of
nominal DKK 1 and DKK 77.00 per share for 17,981 of the new shares of nominal
DKK 1. The total proceeds to Zealand from the capital increase amounts to DKK
4,554,204.60.

Each new share of nominal DKK 1 carries one vote at Zealand’s general meetings.
The new shares give rights to dividend and other rights from the time of the
warrant holder's exercise notice.

The new shares will be listed on Nasdaq Copenhagen following registration of
the capital increase with the Danish Business Authority, upon which the share
capital of Zealand will be nominal DKK 23,471,587 divided into 23,471,587
shares with a nominal value of DKK 1 each.

The amendment of Zealand’s Articles of Association entailed by the share
capital increase has today been registered with the Danish Business Authority.
The new Articles of Association are attached to this announcement and are also
available on the company’s website: www.zealandpharma.com.

The content of this announcement has no impact on the company’s financial
outlook for 2015.

                                  ?????

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, email: bmj@zealandpharma.com

Hanne Leth Hillman, Senior Vice President for Investor Relations &
Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen, Denmark. Zealand has leading expertise in the
discovery, design and development of novel peptide medicines and possesses
in-house competences in clinical trial design and management with a therapeutic
focus on metabolic diseases and acute care indications. The company is
advancing a pipeline of novel wholly-owned medicines alongside a partnered
product and development portfolio.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as
Lyxumia® and in Phase III development as a single-injection combination with
Lantus® (LixiLan), both under a global license agreement with Sanofi. US
regulatory submission of Lyxumia® is planned for Q3 2015 and US/EU regulatory
submissions for LixiLan in Q4 2015.

Zealand’s wholly-owned pipeline include danegaptide (prevention of Ischemic
Reperfusion Injury) in Phase II and the stable glucagon analogue, ZP4207 in two
Phase I trials as a single-use rescue pen (severe hypoglycemia) and a
multiple-dose version (mild to moderate hypoglycemia) as well as several
preclinical peptide therapeutics. Partnering represents an important component
of strategy to leverage in-house expertise, share development risk in large
clinical trials, provide funding and commercialize the company’s products.
Zealand currently has global license agreements and partnerships with Sanofi,
Helsinn Healthcare and Boehringer Ingelheim.

For further information: www.zealandpharma.com Follow us on Twitter
@ZealandPharma